Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02

The activity of single-agent targeted molecular therapies in glioblastoma has been limited to date. The North American Brain Tumor Consortium examined the safety, pharmacokinetics, and efficacy of combination therapy with sorafenib, a small molecule inhibitor of Raf, vascular endothelial growth fact...

詳細記述

保存先:
書誌詳細
主要な著者: Lee, Eudocia Q., Kuhn, John, Lamborn, Kathleen R., Abrey, Lauren, DeAngelis, Lisa M., Lieberman, Frank, Robins, H. Ian, Chang, Susan M., Yung, W. K. Alfred, Drappatz, Jan, Mehta, Minesh P., Levin, Victor A., Aldape, Kenneth, Dancey, Janet E., Wright, John J., Prados, Michael D., Cloughesy, Timothy F., Gilbert, Mark R., Wen, Patrick Y.
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2012
主題:
Clinical Investigations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3499017/
https://ncbi.nlm.nih.gov/pubmed/23099651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos264
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料